Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Histamine H3 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Histamine H3 receptor | 445 aa | 384 aa | 22.4 % |
Echinococcus granulosus | biogenic amine 5HT receptor | Histamine H3 receptor | 445 aa | 405 aa | 25.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0044 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0044 | 0.5 | 0.5 |
Giardia lamblia | Synaptic glycoprotein SC2 | 0.0044 | 0.5 | 0.5 |
Echinococcus multilocularis | 3 oxo 5 alpha steroid 4 dehydrogenase, C terminal | 0.0044 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0044 | 0.5 | 0.5 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0044 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Entamoeba histolytica | trans-2,3-enoyl-CoA reductase, putative | 0.0044 | 0.5 | 0.5 |
Plasmodium vivax | polyprenol reductase, putative | 0.0044 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0044 | 0.5 | 0.5 |
Entamoeba histolytica | 3-oxo-5-alpha-steroid 4-dehydrogenase domain-containing protein | 0.0044 | 0.5 | 0.5 |
Echinococcus granulosus | synaptic glycoprotein sc2 | 0.0044 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0044 | 0.5 | 0.5 | |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0044 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Plasmodium vivax | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Brugia malayi | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | 0.0044 | 0.5 | 0.5 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0044 | 0.5 | 0.5 |
Plasmodium falciparum | polyprenol reductase, putative | 0.0044 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0044 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0044 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.5 | 0.5 |
Echinococcus granulosus | 3 oxo 5 alpha steroid 4 dehydrogenase C terminal | 0.0044 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0044 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0044 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0044 | 0.5 | 0.5 |
Echinococcus multilocularis | synaptic glycoprotein sc2 | 0.0044 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | > 10 mg kg-1 | In vivo inhibition of brain N-methylhistamine formation in mice when administered perorally in presence of oxalate salt | ChEMBL. | 15163206 |
ED50 (functional) | > 10 mg kg-1 | In vivo inhibition of brain N-methylhistamine formation in mice when administered perorally in presence of oxalate salt | ChEMBL. | 15163206 |
Intrinsic activity (functional) | < 0.1 | In vitro intrinsic activity of the compound against histamine H3 receptor using [3H]-Histamine as radioligand from rat cerebral cortex synaptosomes with respect to histamine; No detectable agonism | ChEMBL. | 15163206 |
Intrinsic activity (functional) | < 0.1 | In vitro intrinsic activity of the compound against histamine H3 receptor using [3H]-Histamine as radioligand from rat cerebral cortex synaptosomes with respect to histamine; No detectable agonism | ChEMBL. | 15163206 |
Ki (binding) | = 108 nM | In vitro inhibitory activity against against histamine H3 receptor using [3H]-Histamine as radioligand from rat cerebral cortex synaptosomes | ChEMBL. | 15163206 |
Ki (binding) | = 108 nM | In vitro inhibitory activity against against histamine H3 receptor using [3H]-Histamine as radioligand from rat cerebral cortex synaptosomes | ChEMBL. | 15163206 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.